A subthreshold ischemic insult applied to an organ such as the heart and/or brain may help to reduce damage caused by subsequent ischemic episodes. This phenomenon is known as ischemic tolerance mediated by ischemic preconditioning (IPC) and represents the most powerful endogenous mechanism against ischemic injury. Various molecular pathways have been implicated in IPC, and several compounds have been proposed as activators or mediators of IPC. Recently, it has been established that the protective phenotype in response to ischemia depends on a coordinated response at the genomic, molecular, cellular and tissue levels by introducing the concept of ‘genomic reprogramming’ following IPC. In this article, we sought to review the genetic expression profiles found in cardiac and cerebral IPC studies, describe the differences between young and aged organs in IPC-mediated protection, and discuss the potential therapeutic application of IPC and pharmacological preconditioning based on the genomic response.

Genetics and genomics of ischemic tolerance: focus on cardiac and cerebral preconditioning / Della Morte, D; Guadagni, F; Palmirotta, R; Testa, G; Cacciatore, F; Abete, Pasquale; Rengo, F; Perez Pinzon, M; Sacco, Rl; Rundek, T.. - In: PHARMACOGENOMICS. - ISSN 1744-8042. - 15:(2012), pp. 1741-1757. [10.2217/pgs.12.157]

Genetics and genomics of ischemic tolerance: focus on cardiac and cerebral preconditioning

Cacciatore F;ABETE, PASQUALE;
2012

Abstract

A subthreshold ischemic insult applied to an organ such as the heart and/or brain may help to reduce damage caused by subsequent ischemic episodes. This phenomenon is known as ischemic tolerance mediated by ischemic preconditioning (IPC) and represents the most powerful endogenous mechanism against ischemic injury. Various molecular pathways have been implicated in IPC, and several compounds have been proposed as activators or mediators of IPC. Recently, it has been established that the protective phenotype in response to ischemia depends on a coordinated response at the genomic, molecular, cellular and tissue levels by introducing the concept of ‘genomic reprogramming’ following IPC. In this article, we sought to review the genetic expression profiles found in cardiac and cerebral IPC studies, describe the differences between young and aged organs in IPC-mediated protection, and discuss the potential therapeutic application of IPC and pharmacological preconditioning based on the genomic response.
2012
Genetics and genomics of ischemic tolerance: focus on cardiac and cerebral preconditioning / Della Morte, D; Guadagni, F; Palmirotta, R; Testa, G; Cacciatore, F; Abete, Pasquale; Rengo, F; Perez Pinzon, M; Sacco, Rl; Rundek, T.. - In: PHARMACOGENOMICS. - ISSN 1744-8042. - 15:(2012), pp. 1741-1757. [10.2217/pgs.12.157]
File in questo prodotto:
File Dimensione Formato  
2012 b, Pharmacogenomics.pdf

non disponibili

Tipologia: Versione Editoriale (PDF)
Licenza: Accesso privato/ristretto
Dimensione 3.11 MB
Formato Adobe PDF
3.11 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11588/513605
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 32
  • ???jsp.display-item.citation.isi??? 31
social impact